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CLINICIAN’S GUIDE TO PATHOGENESIS OF ARV
RESISTANCE
The HIV reverse transcriptase enzyme lacks a proof-reading
capability. This is the key to both the virus’s rapid evolution,
causing highly effective and continued evasion of the immune
system, and the rapid development of drug resistance.
Depending on the stage of the disease, up to 10 billion HIV
virions are produced in HIV-positive people every day. Each
virion has a half-life of about 30 minutes. The viral swarm
consumes huge numbers of lymphocytes every day. 
The genetic strand that codes for the virus is 10 000 nucleic
acid base pairs long, and a mistake occurs, on average,
approximately every 10 000 translations. The absence of the
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Both private and public sector see a bewildering clinical array of patients taking failing antiretroviral (ARV) regimens. We intend
this article to provide a practical guide to help clinicians understand and manage ARV drug resistance in an African context.
ARV resistance is a rapidly evolving field, requiring expertise in dealing with a wide range of situations. Much of the
information we have on ARV resistance is from populations in the developed world where clade B is the biggest problem, while
in most of Africa clade C is the commonest infection.
Southern Africa is faced with the daunting prospect of putting several hundred thousand people on ARV therapy (ART) in the
next few years.1 ART is the only effective option available to people with advanced HIV disease, and is remarkably effective in
improving quality of life, increasing lifespan, dramatically decreasing the burden of opportunistic disease, and returning people
to productive life.2
The levels of adherence demanded by ARV regimens are extremely high relative to any other chronic disease. The South African
government’s Comprehensive Care for HIV/AIDS in the Public Health Sector3,4 programme has a ’second-line’ ARV regimen
(Fig. 1), specifically as a safety net for people failing the first-line regimen. Other countries do not have this luxury. The SA
second-line regimen is more difficult to take, has greater toxicity, and is more expensive than the first-line treatment.
ARV resistance often compromises future treatment options. The choice of regimens in the SA programme maximises the use
of available drugs in this country.
Our experience of private practitioners in South Africa is that they use a range of drug regimens other than those
recommended in the government guidelines. There is no effective mechanism to enforce use of the government’s
recommended drug regimens, but we feel that they are the most rational use of drugs currently available in SA and that
deviation from guidelines in routine use should be discouraged, unless alternative options exist. AZT/3TC is still a popular
combination, and there are excellent data to support its use as the nucleoside reverse transcriptase inhibitor (NRTI) backbone
in first-line therapy, but the alternatives available when resistance to this option develops (i.e. d4T with ddI) are very toxic. In
other countries, alternative regimens may be more appropriate.
While we have focused on adult ARV choices in this article, the same principles generally hold for children, although choice of
drugs is currently different. Again, we recommend the use of the SA guidelines, published in the November 2005 Journal.
proof-reading function means that, on average, there is a
nucleic acid mutation in every single copy of the virus. It is
estimated that every known mutation occurs 10 000 to
100 000 times in every person with untreated HIV every single
day.
Mutation rates accelerate when there is accelerated viral
replication – i.e. the faster the virus is produced (e.g. when
someone has tuberculosis), the more mistakes are made. Some
mutations are useful to the virus, allowing it to duck and dive
away from the antiviral properties of the immune system and
ARV drugs. Other mutations (in fact, most) are harmful,
making it more susceptible to both the immune system and/or
ARVs. These weakened forms are rapidly outcompeted, as the
fittest version exercises its replicative advantage and
outgrows the competitors.
Of course, some progeny will have no mutations while others
will have multiple changes, but the massive replication means
that selection for more virulent strains is inevitable: what has
been termed a ’predetermined agenda’. This leads to the
development of quasispecies, HIV ’gangs’ competing against
each other for the same turf in the human host. The term ‘wild
type’ refers to the most effective gang that exists in the
absence of ARVs and the absence of significant ARV
mutations. ‘Fitness’ reflects how much replicative ability the
virus has. The ‘fittest’ wild type will prevail, unless something
comes along that changes the natural order of things – like an
ARV drug.
It has been estimated that untreated HIV-positive people have
every known ARV resistance mutation somewhere in their
bodies at any given moment, despite never having been
exposed to ARVs! This occurs by pure chance – the
‘predetermined agenda’. However, in the absence of ARV
selection pressure, these quasispecies cannot out-compete the
wild-type strain.
WHAT IS ARCHIVING?
At each step, replicatively effective viral DNA is ‘archived’, or 
integrated into non-replicating or slowly replicating cells
throughout the body (e.g. memory T cells and macrophages).
This means that the body houses a memory bank of all
effective virus quasispecies it has witnessed within its tissues.
If a potent selection pressure inhibits the ‘wild-type’ virus, and
the ‘archived drug-resistant virus’ starts to replicate, it can
rapidly spread and become the predominant quasispecies. It
seems that resistance mutations to some drugs are
‘remembered’ (archived) in the host human DNA better than
others, but, disastrously, ARV drug resistance can be
uncovered after many years of effective viral suppression.
So why do the ARVs work at all, given all this mutagenic
ability? Many mutations (but not all) interfere with the virus’s
replicative and infectious ability. A virus with several
mutations to exposed drugs may be so crippled that it is
unable to be viable (Fig. 2). 
IS DRUG RESISTANCE LIKELY TO BE A MASS
PROBLEM IN AFRICA?
Probably, but mathematical modelling suggests not for at least
a decade, and that the impact may be limited.5,6 The spectre of
some sort of a multidrug-resistant, super-infectious, super-
virulent super-virus is the stuff of newspaper headlines, but
has never been reliably identified. In Europe and America, as
treatment evolved during the late 1980s and early 1990s,
ARVs were initially used as monotherapy, then as dual therapy,
resulting in a high background prevalence of NRTI resistance
in treatment-experienced patients. More recently, even some
triple combinations (e.g. AZT/3TC/ABC, Trizivir) have been
shown to be associated with a high likelihood of treatment
failure and development of resistance. Along with this,
patients on ARVs in developed countries have a high rate of
non-adherence, making the general community resistance to
everyday commonly used ARVs a big problem. Interestingly, it
seems that community resistance to ARVs in developed
countries may be on the wane – possibly because the use of
more potent cocktails decreases the transmissibility of drug-
resistant virus.7,8 However, on deeper analysis of the patterns
of transmitted resistance it appears that non-nucleoside
reverse transcriptase inhibitor (NRTI) community resistance is
steadily increasing, while other class mutations are
decreasing. 
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Fig. 1.  South African government 2004 recommendation for
sequencing of ARVs; nevirapine use for women wanting/at risk
of pregnancy.
Fig. 2.  The evolution of HIV resistance.
However, individual patients with drug-resistant virus are
already cropping up in South Africa, and several case and
anecdotal reports have emerged of people with mutations
associated with severe drug resistance.9,10 These patients are
difficult and expensive to manage. It is every clinician’s
responsibility to reduce the community prevalence of
resistance by looking after their patients responsibly and
carefully, checking adherence at every visit, avoiding drugs
that interfere with ARV metabolism, and checking the viral
load regularly. This is the same model as for TB treatment –
multidrug-resistant (MDR) TB is a product of poor adherence
and poor patient follow-up by the health services. HIV evolves
resistance much faster than TB, so poor management is likely
to have rapid consequences.
In future, as is the case in developed countries, we may begin
recommending routine resistance testing of infected people.
At present, this is probably unnecessary in the vast majority of
patients.
KNOWING THE ENEMY: SIGNATURE MUTATIONS
HIV specialists, like other medical professionals, are addicted
to deep and impenetrable jargon. There are over 200 known
resistance mutations, and new ones are being described all the
time. However, there is little point in remembering the
mutations. It is necessary to understand the drugs you use,
and then how to spot and deal with resistance. 
We believe that the average clinician needs to know how
quickly resistance develops to the ARVs they use regularly, and
the clinical implications of that resistance. For the sake of
completeness, we will cover the more common resistance
mutations, and explain how the nomenclature evolved.
The enzyme reverse transcriptase transcribes viral RNA to
DNA. The reverse transcriptase gene is 560 amino acids long.
A common resistance mutation to the drug 3TC is at the 184
location, where valine replaces methionine. This is called
M184V (methionine is the ‘normal’ nucleic acid replaced at
position 184 with valine). Simlarly, K103N is a mutation to
NNRTIs in adults, with lysine (K) replaced at position 103 with
asparagine (N). The first letter is sometimes left off, as
shorthand – i.e. 184V, 103N.
Proteases assemble the virus in the cytoplasm. The protease
gene is only 99 amino acids long, and a D30N would imply
aspartic acid (D) is replaced with asparagine (N) at position 30.
This is a common mutation associated with the protease
inhibitor nelfinavir.
The term ‘drug resistance’ as a blanket term is fuzzy – it may
be total or partial, depending on the drug, and resistance to
one drug may even confer increased susceptibility to another.
The nomenclature is further confused by terms such as ‘major’
and ‘minor’ mutations, or ‘primary’ and ‘secondary’ mutations,
muddled even further by the fact that the field is evolving so
fast that new insights often make these terms archaic before
they enter common use. To make life even more difficult,
different clades seem to have different patterns in the
development of resistance. Luckily, the resistance patterns
tend to consign themselves to a distinct class, although some
subtle overlaps are starting to emerge. These are not yet of
clinical significance.
Three classes of drugs are currently available in southern
Africa.
1. THE NON-NUCLEOSIDE REVERSE TRANSCRIPTASE
INHIBITORS
Nevirapine and efavirenz are widely used in southern Africa
and throughout the world. The drug binds directly to the
reverse transcriptase enzyme, rendering it ineffective. The
commonest mutation in the reverse transcriptase gene
stabilises the site that binds the enzyme, making it less able to
bind effectively. New NNRTI drugs in development are able to
bind despite this mutation.
Resistance to this class is the easiest to understand –
resistance occurs rapidly (often after a single dose if used
alone). There is complete class resistance, so complete
resistance to efavirenz means that nevirapine is useless, and
vice versa. 
There are several NNRTI resistance mutations, almost all
contributing profound resistance throughout the class – the
commonest is K103H, and another is Y181C. A distinct
mutation has been described to clade C virus (V106M) which
is the predominant clade in SA, and this resistance mutation
has been described in this the country.11,12 Only one point
mutation is necessary to cause complete resistance to both
efavirenz and nevirapine. The resistance mutations
unfortunately do not seem to alter the virus’s replicative
ability, and transmission of resistance from one person to
another is of major concern – the mutation does not affect
fitness.
The use of nevirapine for the prevention of mother-to-child
transmission deserves special mention in southern Africa.
Large numbers of women are being exposed to this treatment,
which involves a single dose of nevirapine to the mother
during labour, and a postpartum dose to the neonate. It is
remarkably effective and safe in preventing transmission to
unborn children, but high rates of nevirapine resistance
mutations have been described months after adminis-
tration.13,14 This makes sense, as only a single mutation confers
resistance, and the drug has a very long half-life, meaning
that the virus is exposed to it for a prolonged period (resulting
in several days of nevirapine monotherapy), increasing the
period of selection pressure. A trial done in Thailand suggests
that women with mutation may be at high risk of failing a
subsequent NNRTI-based regimen.15 However, the evidence is
not completely clear-cut, and the World Health Organization
and local experts are currently reviewing the guidelines and
evidence as it emerges. Until clear guidelines are available, it is
probably acceptable to treat women treated with single-dose
nevirapine and subsequently with regimen 1a as if they had
not been exposed.
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In summary: NNRTI resistance is of major clinical significance
– it is easy to mess it up; mess it up, and you confine this very
useful class to the dustbin of options.
2. NUCLEOSIDE REVERSE TRANSCRIPTASE
INHIBITORS – THESE DRUGS MIMIC DNA’S BUILDING
BLOCKS
d4T and 3TC are part of the South African Department of
Health (DoH) first-line regimen, AZT and ddI are part of the
DoH’s second-line regimen (see Fig. 1). Other drugs used in SA
include abacavir. Tenofovir (TDF), a new variation in the NtRTI
class with a unique resistance profile, is eagerly anticipated as
a once-daily and safe alternative to d4T. TDF (a nucleotide RTI)
shares resistance mutations with ddI and ABC (K65R), and is
rendered ineffective by NRTI-class resistance mutations.
Resistance to NRTIs is far more complex. There is cross-
resistance between some drugs in this class, and none for
others. Resistance mutations occur on the reverse
transcriptase enzyme. These are often far from the area coding
for the active site, but induce conformational changes that
have indirect changes at the active site making it more
‘discerning’ towards NRTIs, or facilitate the removal of the
drug from the binding site.
The easiest to understand is resistance to 3TC. A single
mutation, the famous M184V mutation, confers complete
resistance to 3TC, similar to the way a single mutation confers
complete resistance to the NNRTIs. The 184 mutation can also
occur in the presence of emtricitabine (FTC, a new NRTI, not
yet available in SA but very similar to 3TC), abacavir, and
occasionally ddI. Its impact on ddI and abacavir is far less
profound than on 3TC. Also similar to NNRTIs, resistance
occurs rapidly, although it tends to occur at a slightly slower
pace, usually within weeks of exposure to 3TC in the presence
of a detectable viral load.
There is one potentially important difference to the NNRTIs:
the M184V mutation seems to deeply affect the pathogenicity
and possibly the transmission potential of the virus. There is
interest in keeping people on 3TC even if they are resistant to
it, in salvage therapy, usually after failure of two regimens. The
M184V virus that one sees in the blood of patients on failing
3TC-containing regimens is less ‘fit’, and more easily
controlled by the immune system and subsequent drug
treatments. While the M184V mutation makes the drug
slightly less effective than abacavir and ddI, it seems to
’sensitise’ HIV to AZT, ddT and tenofovir. Increasingly,
experienced clinicians are using it as a viral ‘crippler’, adding a
triple cocktail on top of the 3TC therapy. Evidence for this is
sparse at present, but 3TC is regarded as a safe drug, and
adding it on seems to make sense. However, until clearer
guidelines are available it should only be done in consultation
with an expert.
The situation with the ’thymidine analogues’ AZT and d4T is
more complex. Both drugs have cross-resistance, and both
need several mutations before clinically important resistance
occurs. This often takes several months of unopposed non-
suppressive treatment, and resistance therefore accumulates
serially. Resistance mutations to these are known snappily as
TAMs (or, less snappily, as thymidine analogue mutations).
Examples include the bewildering array of 41L, 67N, 70R,
210W, 215 Y/F and 219Q/E. ‘TAM’ is probably a misnomer, as
these mutations affect more than d4T and AZT, and may
decrease the efficacy of other nucleosides including
didanosine, tenofovir and abacavir, although other NRTI
mutations are necessary. The development of mutations at
area 69 (most commonly T69S) confers variable low-level drug
resistance against almost all nucleosides, but this seems to
increase the impact of subsequent mutations. Interestingly,
TAMs seem to have no effect on the efficacy of 3TC, and the
combination of AZT, 3TC and a potent third drug like Kaletra
appears to be very effective even when several TAMs are
present.
So called ’non-thymidine’ mutations include K65R, which is
selected by tenofovir and reduces susceptibility to all NRTIs
except AZT, where it improves sensitivity; and Q151M and
L74V, which decrease the efficacy of a range of NRTIs.
Didanosine (ddI) has a high resistance barrier, requiring serial
mutations before it loses efficacy, and tends to select mainly
for L74V. Abacavir is a ’dirty’ drug, as the resistance mutations
to it are very difficult to predict clinically. Multiple TAMs and
the K65R mutation, however, are likely to decrease the
effectiveness of abacavir.
In summary: Unlike the NNRTIs, resistance is not generally
catastrophic. However, it is much more complex, and
approaches to resistance are steadily becoming more
sophisticated, dealing with issues of cross-resistance, partial
’revertants’ and hypersusceptibility.
3. PROTEASE INHIBITORS (PIs)
Generally the PIs require multiple mutations to acquire
resistance. They are the ’tough guys’ of the ARV revolution, but
some are tougher than others.
‘Boosting’ is the term used to describe increasing the level of
PIs by adding ritonavir to the mix. This dramatically increases
the blood concentrations, and makes development of
resistance much more difficult. The ritonavir role is
pharmacological only – it has minimal ARV activity at this very
low dose. Boosting seems to protect against the development
of multiple PI mutations. Interestingly, this strategy also seems
to protect other classes of drugs, especially the nucleosides,
from developing resistance. Nelfinavir is the only PI not
’boostable’ – the addition of ritonavir only marginally
increases the blood levels.
New mutations to PIs are being described, and clinicians have
begun classing mutations into ’major’ and ’minor’ – based on
how much the mutation actually stops the action of the drug.
As mentioned above, this nomenclature is challenged by the
new information on these mutations. It is often possible to
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change one PI for another, much like the nucleoside
analogues, although resistance testing makes this less like
guesswork. Kaletra (lopinavir/ritonavir), used in the South
African rollout, appears to need more than 6 mutations to
acquire resistance, while nelfinavir usually requires only 1 to
reduce its efficacy 5-fold, and 2 to reduce it 50-fold. Some PIs
need specific mutations, but the common mutations occur at
positions 82, 84 and 90. 
A new PI, atazanavir, appears to induce a mutation (150L) that
actually increases susceptibility to other PIs. This has also been
described with saquinavir and amprenavir. Whether this is
clinically useful is still up for debate.
So what to do? There is lots of clinical debate about which PI
is best to start with, and which to use next. It appears that we
may have third- and fourth-line choices now, and the old ’one
strike and you’re out’ has evolved into a place where it seems
that certain PIs may even be recycled, despite archiving, a
theory considered heresy a few short years ago. New PIs are
on the horizon, with new resistance profiles. If these drugs
were less toxic, the future would seem rosy.
Bottom line: In South Africa the national guidelines use
Kaletra, the ARV equivalent of the Great Wall of China. Failing
this drug is very difficult, but is possible (the first patient to
fail it was described from SA!9). Other PIs can then be used in
its place, although these do not form part of the national
guidelines. Generally, the world is moving away from indinavir
and saquinavir, because of toxicity and because the resistance
profile is ‘dirty’, influencing the choice of future regimens.
Once the first PI regimen has failed, it is not recommended
that nelfinavir, unboosted atazanavir or unboosted amprenavir
is used, as cross-mutations to these make them less likely to
succeed. However, ‘sequential’ PIs can be used. Atazanavir and
amprenavir will probably soon become available in SA. Experts
are increasingly using ‘double-boosted’ PIs, sneakily adding
two PIs to a single dose of rintonavir – but it is not clear which
two PIs to add to the ritonavir, although lopinavir and
saquinavir are popular.
In summary: We feel NNRTIs are more appropriate than PIs
initially, for reasons of ease of use, toxicity and cost. We
advocate lopinavir/ritonavir as the first PI you use, and then
suggest you consult expert help for the next choice. Let’s hope
that by then we’ll have sorted out the bewildering array of
options available.
ROLE OF DRUG INTERACTIONS AND DRUG
RESISTANCE
Drug interactions may decrease the effective dose of certain
ARVs, leading to resistance. TB drug co-administration is
common, as patients enter the programme from TB
programmes, or get placed on rifampicin-containing regimens
after developing immune reconstitution syndromes.
Rifampicin, NNRTIs and PIs all affect CYP 3A4 and therefore
can decrease the plasma levels. Rifampicin administration
increases efavirenz and nevirapine metabolism and
theoretically could drop levels leading to potential dual
therapy. Some authorities recommend increasing the dose of
efavirenz in the presence of rifampicin, but evidence suggests
that this is unnecessary. The current South African guidelines
suggest no dose adjustment of efavirenz, and our anecdotal
experience is that this is correct. Similar concerns with Kaletra
exist, and here the SA guidelines suggest adding a whopping
300 mg ritonavir bd to the standard Kaletra dose, to counter
the accelerated metabolism.2,3,16-19
IS DRUG RESISTANCE TESTING AN OPTION?
The answer to this is a highly qualified yes. Genotypic
resistance testing is available through a large number of
laboratories in SA, but not in the DoH rollout, as the benefit is
not felt to justify the cost. 
Genotype testing involves the extraction and amplification of
the predominant viral genome in the blood, and seeing if
known genetic mutations to ARVs are present. The weakness
of the testing is that it does not detect archived virus, may
miss small populations of resistant virus in the blood, only
detects known resistance mutations, takes time and is
expensive. The test should ideally be done while still on the
‘failing’ regimen, otherwise ‘wild’ non-resistant virus may
obscure the smaller population of resistant virus. There must
be enough virus to do the test (at least 1 000 copies/ml).
Results have to be interpreted against an accurate history of
ARV use, and must be interpreted by an expert in the field.
Resistance testing is useful on a population basis, for the
surveillance of prevalent drug resistance, but our experience is
that most of these tests, when ordered by non-experts, are a
waste of money and time. In the hands of experts, they may
add to the chance of success of a subsequent ‘best guess’ ARV
regimen.
The rule is: Do not order a resistance test unless you have
spoken to an expert.
Phenotypic resistance testing is more analogous to a
conventional microscopy, culture and sensitivity (MC&S) most
clinicians are very familiar with, with the virus grown against
different types and concentrations of antiretrovirals.
Unfortunately, it is expensive and currently only available in
research laboratories in developed countries. ‘Virtual
phenotyping’ uses genotyping and match genotypes to brown
phenotypes and ARV history to predict overall resistance
patterns, and may hold promise for improved use of genotype
testing in the future.
DOES STOPPING ARVs SUDDENLY CAUSE
RESISTANCE?
This is a thorny issue. The commonest reason for stopping 
treatment is possible toxicity, or running out of funding for
treatment.
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Consider a patient on d4T, 3TC and efavirenz (Fig. 3): If you
suddenly stop treatment, the level of d4T drops very soon, as
it has a short half-life, leaving the patient effectively on 3TC
and efavirenz (dual therapy). Then the levels of 3TC drop, and
the only effective drug left is efavirenz. Efavirenz has a half-
life that lasts days and occasionally weeks, and has a very low
resistance barrier, so it makes sense that resistance will
develop quickly. Preliminary studies have demonstrated
resistance, but it is unclear whether this is clinically important.
Many clinicians now ‘cover the tail’ – they continue the drugs
with high resistance barriers to cover the vulnerable NNRTIs
(see Fig. 4). No one is sure how long we should continue these
(although many of us use a week), or even if it is effective. If
the drug level of efavirenz dropped suddenly, and you’re left
with just d4T and 3TC for a few days, significant resistance is
unlikely. The difficulty with this is that if you are stopping due
to NRTI toxicity, e.g.pancreatitis, you would need to stop the
NRTIs at the same time.
In many situations it is not practical to cover the tail,
especially if there is severe illness where it is unclear whether
it is a drug reaction or immune reconstitution. In these cases,
rather stop all the drugs, and pick up the resistance pieces
once the crisis is over.
CAN I DELIBERATELY CRIPPLE THE VIRUS?
The 3TC mutation appears to decrease viral fitness, and
may even make other drugs more potent, especially AZT, d4T
and tenofovir. If there is existing 3TC resistance, some
clinicians (including ourselves) continue 3TC, adding it to the
next regimen as a way of decreasing fitness. Do not add 3TC
as a viral crippler if there is no resistance to it – use it as a
normal ARV!
HOW LONG DOES RESISTANCE PERSIST FOR?
Resistance mutations acquired sexually from someone else
(i.e. passed directly on) seem to persist for much longer than
those found when selected by the virus. Resistance usually
‘disappears’ slowly from the bloodstream, as wild or fitter virus
comes back in the absence of ARVs. Some mutations disappear
before others – the 3TC mutation M184V disappears within a
few weeks, while others can persist for years.
WHAT ABOUT DOING DRUG LEVELS?
Therapeutic drug monitoring (TDM) is not yet generally
available to southern African clinicians. It seems likely that it
will be very useful in the future, especially in dealing with
complex drug interactions, side-effects, or difficult
physiological conditions (such as pregnancy), and where
genetic or other factors impact on plasma levels. In the case of
PIs in particular, this may make life significantly easier. Testing
is not available for the NRTIs. Watch this space for future
recommendations regarding TDM.
A PRACTICAL APPROACH TO A PATIENT FAILING
THEIR FIRST REGIMEN
Questions to ask when faced with a patient on ARVs and
possible drug resistance ...
1. HOW DO YOU KNOW THAT THE PERSON IS
RESISTANT?
A viral load persistently detectable on stable treatment
generally equates to resistance. Remember that it takes 3 - 4
months for the viral load to ‘decay’ (although an effective
regimen should cause a 1.5 log10 drop in viral load after 4
weeks).
It is generally wise to confirm the elevated viral load, by
repeating the test. Many people have viral ‘blips’ or sudden
increases for some reason, and occasionally the test can yield
a falsely elevated level. Confirm the increase before
substituting the regimen.
If someone has a detectable viral load, and you know or
suspect that the patient has interrupted therapy, or is not
completely adherent, or has a drug interaction, or is
inadequately dosed, intensify adherence support, sort out the
problem and measure the viral load a few weeks later. If it
Fig. 3.  Different half-lives mean that triple therapy can evolve
into dual and monotherapy ...
Fig. 4.  Cover the tail! How to stop drugs with different half
lives ...
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becomes undetectable, you have probably avoided an
unnecessary drug substitution. 
However, a persistently raised viral load usually means drug
resistance and you need to consider a change. In the SA
programme, a persistently raised viral load above 5 000 copies
(preferably measured on two occasions 4 weeks apart) should
signal the need for a change.
2. WHAT CLASSES OF DRUGS IS THE PERSON ON?
Resistance is fairly predictable (see Fig. 3). NNRTIs are very
vulnerable, and a single mutation confers complete resistance.
This is usually the first class to show resistance.
Next is usually 3TC, which is also vulnerable to a single
mutation.
The other drugs (nucleosides and PIs) generally follow, albeit
slowly. It usually takes months to develop resistance to these.
Resistance testing is useful to show whether there is actually
resistance to NNRTIs and 3TC, and how much resistance there
is to the other nucleosides and PIs, if any.
3. HOW LONG HAS THE PATIENT BEEN ON THIS
REGIMEN?
If only a few months, it is unlikely that significant resistance
will have accumulated to anything other than the NNRTI and
3TC. However, if a patient has been left on a failing regimen
for many months, the other drugs in the regimen are
increasingly likely to have resistance mutations develop
against them.
4. WHAT ARE YOUR OPTIONS NEXT?
If you have resistance testing results and it has been done
properly, consult with an expert.
If resistance testing is not an option:
■ Consider using a boosted PI. The resistance barrier in this
class is significant.
■ Consider adding 3TC as a ‘crippler’ – but only if you are
sure you have pre-existing viral resistance.
■ Consider new drugs – consult with an expert, as a host of
new drugs are eagerly awaited in the next few years. Or ask
around if a clinical trial is being conducted.
■ Consider a treatment interruption. In some cases,
interrupting therapy seems to allow for some resistance to
wane, and for future options to be more effective. Again,
get expert help – consider the indication for the original
decision to start ARVs; the risk of illness and decline in CD4
must be weighed carefully against the benefit. 
■ Finally, consider just leaving them on the regimen – if
there are no other options. It is clear that patients with
resistant virus left on their failing regimens live longer and
better.20,21
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